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Abstract
Myocardium consists of diverse cell types suggesting a role for cell-cell interaction in maintaining the structural and
functional integrity of the heart. Cardiac fibroblasts are the source of extracellular matrix, growth factors and cytokines in
the heart and their interactions with cardiac myocytes are recognized. Their effects on biological responses of endothelial
cells, however, are vastly unexplored. Proliferation of endothelial cells is an essential stage of angiogenesis and contributes to
development of coronary collaterals. This study was designed to evaluate the effect of soluble factors produced by cardiac
fibroblasts on endothelial cell proliferation. Human cardiac fibroblast-conditioned medium (CF-CM) caused a significant
increase (47%, P6 0.0001) in DNA synthesis in human umbilical vein endothelial cells (HUVEC), as determined by
[3H]thymidine incorporation. This effect was dependent on de novo protein synthesis and activation of MAP kinases.
Consistently, CF-CM induced the expression and activation of ERK2 in HUVEC. The CF-CM from which heparin-binding
proteins were removed, had a significantly enhanced stimulatory effect on DNA synthesis in HUVEC compared to that of
‘whole CF-CM’. Western analysis showed the presence of VEGF, bFGF, PDGF, TGF-L1, fibronectin and thrombospondin-
1 in whole CF-CM. The individual immunodepletion of each factor from whole CF-CM showed that all were necessary for
full activity of CF-CM. CF-CM caused a significant reversal of hypoxia-induced inhibition of DNA synthesis and enhanced
expression of survival-associated protein, Bcl2, in HUVEC. Together, these data show that cardiac fibroblasts release
inhibitory and stimulatory factors, the net effect of which is an enhancement of DNA synthesis in endothelial cells. These
results point to the role that cardiac fibroblasts may play in angiogenesis in the heart. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Myocardial cells consist of cardiac myocytes, car-
diac ¢broblasts, endothelial cells and smooth muscle
cells. This diversity of cell types points to the impor-
tance of cell-cell interactions in maintaining the func-
tional and structural integrity of the heart. Cardiac
¢broblasts which constitute the majority of non-my-
ocyte cells in the heart [1,2] are the cellular source of
the extracellular matrix, matrix metalloproteases, an
array of growth factors and several cytokines neces-
sary for cell growth and di¡erentiation [1^7]. Because
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of these properties they have the potential to in£u-
ence growth and di¡erentiation of other cells in the
myocardium. This notion is supported by studies
demonstrating trophic e¡ects of cardiac ¢broblasts
on cardiac myocytes [3,8] and their role in protection
of cardiac myocytes from hypothermia [9]. Studies in
three-dimensional gels have also evaluated the role of
cardiac ¢broblasts in the regulation of angiogenesis
and demonstrated that cardiac ¢broblasts regulate
the in vitro sprouting of vascular endothelial cells
[10]. Angiogenesis or sprouting of new collaterals
from pre-existing microvasculature necessitates a se-
quence of complex and precisely programmed events
that include the release of matrix metalloproteases by
endothelial cells, degradation of basement mem-
brane, proliferation and migration of endothelial
cells into the surrounding tissue and ¢nally recon-
struction of matrix and assembly of endothelial cells
into the capillary tube [11,12]. These intricate and
complex processes require coordinated action of di-
verse growth factors and enzymes. Proliferation of
endothelial cells is an essential stage of angiogenesis
and contributes to the development of coronary col-
laterals in the heart. A balanced vascular endothelial
cell proliferation in healthy heart is maintained by
coordinated expression and function of local and cir-
culating factors with both inhibitory and stimulatory
e¡ects on endothelial cell proliferation. Local factors
are produced by all cells in the heart. However, con-
sidering that cardiac ¢broblasts constitute the major-
ity of non-myocyte cells in the heart, the amount of
local factors produced by cardiac ¢broblasts is pro-
portionately large. Growth factors with an estab-
lished role in promotion or inhibition of endothelial
cell proliferation and di¡erentiation include vascular
endothelial growth factor (VEGF), ¢broblast growth
factor (FGF), transforming growth factor-L (TGF-
L1), platelet-derived growth factor (PDGF) and
thrombospondin-1/2. Of these, TGF-L1 and PDGF
have been shown to be produced by cardiac ¢bro-
blasts [4,7]. The e¡ect of cardiac ¢broblasts on endo-
thelial cell proliferation, however, remains unex-
plored. This study was designed to understand the
role of soluble factors produced by cardiac ¢bro-
blasts, in the regulation of endothelial cell prolifera-
tion.
2. Methods
2.1. Cell culture
Human cardiac ¢broblasts were prepared as pre-
viously described [13]. Human ventricular tissue was
obtained from a recipient of a heart transplant (25
year old white male) who had developed cardiomy-
opathy secondary to viral myocarditis. The unaf-
fected segments of the septum (as determined by
gross pathological examination) were used for prep-
aration of cardiac ¢broblasts as previously described
[13]. The nature of cells was determined by immuno-
£uorescence staining with anti-human factor VIII,
anti-desmin and anti-vimentin for the identi¢cation
of endothelial cells, smooth muscle cells and ¢bro-
blasts, respectively, as previously described [13]. In
early passages [1^3], only 1^2% of cells stained pos-
itively with anti-desmin and anti-factor VIII. All cells
were stained positively with anti-vimentin antibody.
Cells from passages 6^8 were used. At this stage all
cells stain negative for endothelial and smooth
muscle cell markers.
Human umbilical vein endothelial cells (HUVEC)
were purchased from American Type Culture Collec-
tion (VA). Cells were subcultured in F-12K medium
containing heparin (100 Wg/ml), endothelial cell
growth supplement (30 Wg/ml) and 10% fetal bovine
serum (FBS).
2.2. Preparation of cardiac ¢broblast-conditioned
medium (CF-CM)
Human cardiac ¢broblasts were grown in DMEM
in the presence of 10% FBS until con£uent. The
growth medium was then removed, cell layers were
washed with phosphate-bu¡ered saline (PBS) to re-
move all traces of FBS and cells were incubated in
the absence of serum and growth supplements in
F-12K medium for 48 h. The medium (CF-CM)
was collected and £oating cells were separated by
centrifugation under sterile conditions.
2.3. Removal of heparin-binding proteins from ‘whole
CF-CM’
Whole CF-CM was incubated (16 h at 4‡C, with
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constant gentle shaking) with heparin-Sepharose
(A⁄-gel Heparin, Bio-Rad, CA). Heparin-Sepharose
was then removed by centrifugation and the super-
natant was used for its e¡ect on DNA synthesis in
endothelial cells (described below).
2.4. [3H]Thymidine incorporation
HUVEC were grown until con£uent in F-12K me-
dium and 10% FBS on 24-well culture dishes. Cells
were then serum-deprived for 12 h, the medium was
removed and the CF-CM (whole, after passage
through heparin-Sepharose, or after immunoprecipi-
tation of individual factors) was added to the wells in
conjunction with [3H]thymidine (6 WCi/ml), speci¢c
activity 86 Ci/mmol (Amersham, UK) in the presence
or absence of synthetic inhibitor of MAP kinase,
PD98059 [14] (Calbiochem, CA) (25 WM), a synthetic
analogue of RGD, Arg-Gly-Asp-Ser-Pro-Ala-Ser-
Ser-Lys-Pro (Sigma) (100 WM), and cycloheximide
(50 WM). Cells were then incubated for 16 h. At
the end of this period, cells were washed with PBS,
lysed in lysis bu¡er (25% sodium dodecyl sulfate in
10 N NaOH). DNA was precipitated by 5% tri-
chloroacetic acid, ¢ltered, ¢lters were washed and
the radioactivity of the ¢lters was determined by
liquid scintillation counting. The concentration of
DNA was measured by chromogenic method and
spectrophotometry and the amount of radioactivity
was normalized to the concentration of DNA in each
sample, as previously described [15].
2.5. Western analysis
Western analysis of CF-CM and HUVEC lysate
was performed as previously described [16]. CF-CM
was concentrated to 1/50 of its original volume, using
a Microcon Devices YM-10 (Millipore, MA) micro-
concentrator. In the case of HUVEC lysates, con£u-
ent, quiescent HUVEC were incubated with CF-CM
or F-12K medium in the absence or presence of 1 WM
PDBU for 10^60 min. Cells were rinsed three times
with ice-cold PBS and lysed as described previously
[16]. Protein concentration in concentrated CF-CM
and in cell lysate was measured using a BCA protein
assay kit (Pierce, IL) according to the manufacturer’s
guidelines. Electrophoresis on a 10% SDS-polyacryl-
amide gel and electrotransfer of proteins to an Im-
mobilon-P membrane (Millipore, MA) were per-
formed as previously described [16]. After the
transfer, the membrane was incubated for 1 h in
TPBS (PBS, 0.05% Tween 20) containing 1% BSA
and 0.4 Wg/ml of monoclonal antibodies to ERK2,
TGF-L1, Bcl2 and polyclonal antibodies to ERK1,
bFGF and PDGF (AA, BB) (Santa Cruz, CA) or
0.4 Wg/ml of monoclonal anti-phosphotyrosine anti-
body (Upstae Biotechnology), monoclonal anti-
thrombospondin-1 antibody (NeoMarkers, Fremont,
CA) and polyclonal anti-¢bronectin antibody (Cal-
biochem, CA), rinsed with TPBS and incubated
with TPBS containing 1% BSA and 1/20 000 dilution
of a horseradish peroxidase-conjugated goat anti-
mouse IgG (Santa Cruz, CA), or anti-rabbit IgG
(Sigma), depending on the host of primary antibod-
ies. Immunocomplexes were visualized by enhanced
chemiluminescence using the Western Blotting
Chemiluminescence Luminal Reagents kit (Santa
Cruz, CA), according to the manufacturer’s guide-
lines.
2.6. Immunoprecipitation of individual factors from
whole CF-CM
Aliquots (500 Wl) of non-concentrated CF-CM
were incubated with 1 Wg of each speci¢c antibody:
polyclonal (rabbit) anti-human PDGF-B, PDGF-A,
bFGF antibodies (Santa Cruz, CA); a monoclonal
anti-human TGF-L1 antibody (RpD Systems); rab-
bit anti-VEGF165 variant of human VEGF (Santa
Cruz, CA) antibody; monoclonal anti-thrombospon-
din-1 antibody (NeoMarkers); a rabbit polyclonal
anti-¢bronectin antibody (Calbiochem)) and 30 Wl
of Protein A/G-agarose (Santa Cruz, CA) at 4‡C
for 16 h. The immunocomplex was removed by cen-
trifugation at 2500 rpm for 5 min at 4‡C and the
supernatant was used for its e¡ect on DNA synthesis
in HUVEC.
2.7. In-gel kinase assay
In-gel kinase assay was performed according to the
previously described methods [17] and as previously
described by us [16]. The HUVEC lysate was pre-
pared as described in Section 2.5. Aliquots (20 Wg
protein) of cell lysate were electrophoresed in a
10% SDS-polyacrylamide gel containing 0.5 mg/ml
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myelin basic protein (MBP). After ¢xing the gel with
four changes of 20% 2-propanol in 50 mM Tris-HCl,
pH 7.8 for 2 h, SDS was removed by rinsing the gel
in several volumes of 50 mM Tris-HCl, pH 8.0 con-
taining 5 mM 2-mercaptoethanol. The kinases were
then re-denatured with 6 M guanidine HCl and then
renatured by incubating the gel overnight with 50
mM Tris-HCl, pH 8.0 containing 0.04% Tween 40
and 5 mM 2-mercaptoethanol. After preincubation
for 1 h with 40 mM HEPES, pH 8.0 containing
2 mM 2-mercaptoethanol and 10 mM MgCl2, phos-
phorylation of MBP within the gel was achieved by
incubating the gel in 40 mM HEPES, pH 8.0 con-
taining 25 WCi [Q-32P]ATP, 40 WM ATP, 0.5 mM
EGTA, and 10 mM MgCl2. The gel was washed
(5% trichloroacetic acid, 1% sodium pyrophosphate)
until the radioactivity in the wash reached back-
ground levels. The gel was dried at 80‡C and exposed
to X-OMAT-AR (Kodak).
2.8. Statistical analysis
Data from multiple groups were analyzed by one-
way ANOVA followed by a post-hoc test (Sche¡e
test) on individual groups, all possible comparisons
were made, and P6 0.05 was considered signi¢cant.
All calculations were made using Microsoft Ex-
cel+Analyse-it software.
3. Results
3.1. E¡ect of CF-CM on DNA synthesis in
endothelial cells
The e¡ect of CF-CM on DNA synthesis in endo-
thelial cells was determined by the measurement of
[3H]thymidine incorporation into DNA in con£uent
quiescent HUVEC in the presence and absence of
whole CF-CM. The results showed that the addition
of whole CF-CM to quiescent cells led to a signi¢-
cant increase (47%, P6 0.0001) in DNA synthesis in
HUVEC (Fig. 1). This e¡ect was dependent on de
novo protein synthesis, as it was abolished in the
presence of cycloheximide (Fig. 2). The role of
MAP kinases in the CF-CM-induced DNA synthesis
was con¢rmed by data demonstrating the abolish-
ment of CF-CM-induced stimulation of DNA syn-
thesis in HUVEC by a synthetic inhibitor of MAP
kinases, PD98059 (Fig. 1).
Almost all known factors with stimulatory e¡ects
on endothelial cell proliferation are heparin-binding
proteins. To determine the role of heparin-binding
growth factors in CF-CM-induced DNA synthesis
we tested the e¡ect of ‘heparin-depleted CF-CM’
on DNA synthesis. Surprisingly, the results showed
a signi¢cant enhancement (112%, P6 0.0001) in
Fig. 1. E¡ect of CF-CM on DNA synthesis in human endothe-
lial cells. Con£uent, quiescent HUVEC were treated with whole
CF-CM in the presence and absence of cycloheximide (50 WM)
(upper panel) and PD98059 (25 WM) (middle panel). The e¡ect
of cycloheximide (50 WM) and PD98059 (25 WM) on the basal
level of DNA synthesis in untreated cells is shown in the lower
panel. In all experiments DNA synthesis was determined by
measurement of [3H]thymidine (6 WCi/ml) incorporation into
DNA over 16 h as described in Section 2. One-way ANOVA
followed by Sche¡e test, n = 4^6. Values are mean þ S.E.M.
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stimulatory e¡ect of heparin-depleted CF-CM on
DNA synthesis compared with that of whole CF-
CM (Fig. 2). The possibility that this enhancement
is caused by heparin, leaked from Sepharose into the
CF-CM, was ruled out by determining that heparin
alone did not a¡ect DNA synthesis in HUVEC (data
not shown).
To establish that the e¡ects of whole CF-CM and
heparin-depleted CF-CM are indeed caused by fac-
tors of protein nature, both were subjected to heat
denaturation and their e¡ect on DNA synthesis was
subsequently determined. The results showed the loss
of stimulatory activity on DNA synthesis in both
whole CF-CM and heparin-depleted CF-CM after
heat denaturation (Fig. 2), suggesting that the factors
causing the stimulation of DNA synthesis are pro-
teins in nature.
3.2. Release of VEGF, FGF, PDGF, TGF-L1
¢bronectin and thrombospondin-1 by human
cardiac ¢broblasts
Whole CF-CM was ¢rst analyzed for the presence
of growth factors with known e¡ects on endothelial
cell growth and di¡erentiation by Western analysis
using antibodies to VEGF, bFGF, PDGF AA,
PDGF BB and TGF-L1. The results showed that
all factors were present in whole CF-CM and consis-
tent with their heparin-binding properties, their level
in heparin-depleted CF-CM decreased to almost un-
detectable levels (Fig. 3). In addition to growth fac-
tors, we also determined the presence of ¢bronectin,
a matrix component with heparin-binding properties
and known e¡ects on stimulation of DNA synthesis
in endothelial cells [18]. The results showed that
whole CF-CM contains ¢bronectin the level of which
reduces to trace amounts in heparin-depleted CF-
CM (Fig. 3).
The results of DNA synthesis which demonstrated
an enhanced e¡ect of heparin-depleted CF-CM on
DNA synthesis compared with that of whole CF-
CM, suggest that in addition to heparin-binding
growth factors, whole CF-CM also contains hepa-
rin-binding inhibitory factor(s) which, at reduced lev-
els after depletion by heparin, fail to oppose the
stimulatory e¡ects of remaining growth factors in
heparin-depleted CF-CM. To test this possibility,
whole CF-CM was analyzed by Western analysis
for the presence of thrombospondin-1, a heparin-
binding matrix protein and a known inhibitor of en-
dothelial cell proliferation [19]. The results showed
the presence of thrombospondin-1 in whole CF-CM
and its reduced level in heparin-depleted CF-CM
(Fig. 3).
To determine the contribution of each individual
growth factor to CF-CM-induced stimulation of
DNA synthesis, bFGF, PDGF, VEGF, and TGF-
L1 were removed by immunoprecipitation and the
resulting CF-CM was tested for its e¡ect on DNA
Fig. 2. E¡ect of CF-CM on DNA synthesis in human endothe-
lial cells. In the upper panel con£uent, quiescent HUVEC were
treated with [3H]thymidine (6 WCi/ml) in the presence and ab-
sence of whole CF-CM and CF-CM after passage through hep-
arin-Sepharose (hep-CF-CM). The lower panel shows the e¡ect
of whole CF-CM and heparin-depleted CF-CM on DNA syn-
thesis after their heat denaturation. In all experiments DNA
synthesis was determined by measurement of [3H]thymidine in-
corporation into DNA over 16 h as described in Section 2.
One-way ANOVA followed by Sche¡e test, n = 4^6. Values are
mean þ S.E.M.
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synthesis in HUVEC. The results indicated that while
all tested growth factors were necessary for full ac-
tivity of CF-CM, their individual depletion led to
varying degrees of reduction in the stimulatory e¡ect
of CF-CM on DNA synthesis (Fig. 4). Immunode-
pletion of VEGF led to 61% reduction in CF-CM-
induced stimulation of DNA synthesis (Fig. 4). The
removal of PDGF AA, PDGF BB, PDGF A/B,
bFGF and TGF-L1 also diminished the e¡ect of
CF-CM but to a lesser extent (Fig. 4).
To determine the role of ¢bronectin and thrombo-
spondin-1 in CF-CM-induced stimulation of DNA
synthesis they were also removed from whole CF-
CM by immunoprecipitation and the resulting CF-
CM was tested for its e¡ect on DNA synthesis in
HUVEC. Immunodepletion of ¢bronectin from
whole CF-CM led to 76% reduction in CF-CM-in-
duced DNA synthesis (Fig. 4). Immunodepletion of
thrombospondin-1, an established inhibitor of endo-
thelial cell proliferation, which was expected to en-
hance CF-CM-induced DNA synthesis, caused a
modest (27%) inhibition in CF-CM-induced DNA
synthesis (Fig. 4).
Both ¢bronectin and thrombospondin-1 are
known to bind to a variety of surface receptors in-
cluding integrins (K5L1, KvL3, K3L1) and integrin-
associated proteins via RGD sequences in their mol-
ecules. We thus investigated the role of RGD-asso-
ciated interactions in CF-CM-induced DNA synthe-
sis by blocking the RGD binding with a synthetic
peptide containing an RGD sequence. The results
showed that blocking the RGD binding did not
cause a change in CF-CM-induced stimulation of
DNA synthesis in HUVEC (Fig. 5).
3.3. E¡ect of CF-CM on tyrosine phosphorylation and
MAP kinase activation
Most growth factors present in CF-CM are known
to activate the intracellular tyrosine phosphorylation
Fig. 3. Analysis of CF-CM by gel electrophoresis and Western analysis. (A) Western analysis of concentrated CF-CM (80 Wg protein)
on 10% SDS polyacrylamide gel, for bFGF, PDGF (AA, BB), TGF-L1 and on non-reducing gel for VEGF. (B) Western analysis of
concentrated CF-CM (80 Wg protein) on 10% SDS polyacrylamide gel for ¢bronectin and thrombospondin-1. The autoradiographs are
representative of three independent experiments.
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cascade [20]. The e¡ect of CF-CM on activation of
tyrosine phosphorylation was thus tested by Western
analysis of HUVEC lysate for tyrosine phosphorylat-
ed proteins. The results showed the induction of a
phosphorylated protein with apparent molecular
mass of 42 kDa in CF-CM-treated HUVEC in as
early as 10 min, the level of which remained elevated
after 20 min and returned to undetectable levels com-
parable to those in untreated cells after 1 h. This
protein was also induced with 10% FBS and with
PDBU (phorbol 12,13-dibutyrate), an inducer of
MAP kinase activation (Fig. 6). Subsequent Western
analysis of the same blot with anti-ERK1 (44 kDa)
and anti-ERK2 (42 kDa) antibodies indicated that
the phosphorylated protein corresponds to ERK2
(Fig. 6). The activation of ERK2 by CF-CM was
further con¢rmed by the results of separate in-gel
kinase assay which showed increased phosphoryla-
tion of MAP kinase substrate, MBP, at a gel position
corresponding to 42 kDa, in CF-CM-treated cells
over control cells (Fig. 6). The induction of kinase
Fig. 6. E¡ect of CF-CM on tyrosine phosphorylation and MAP
kinase activation in HUVEC. Con£uent, quiescent HUVEC
were treated with CF-CM for the indicated time points and
with VEGF, bFGF and PDBU for 10 min. Cells were then
lysed and the lysate was analyzed for tyrosine-phosphorylated
proteins (A) and ERK2 (B) by Western analysis, using mono-
clonal antibodies to phosphotyrosine (A) and ERK2 (both
phosphorylated and unphosphorylated) (B). Panel C shows the
results of in-gel kinase assay for ERK2 activity as described in
Section 2. These autoradiographs are representative of two in-
dependent experiments.
Fig. 5. E¡ect of CF-CM in the presence of a synthetic analogue
of RGD. Con£uent, quiescent HUVEC were treated with
[3H]thymidine (6 WCi/ml) in the presence and absence of whole
CF-CM. A synthetic analogue of RGD (RGD peptide) was
added to CF-CM at 100 WM. In all experiments DNA synthesis
was determined by measurement of [3H]thymidine incorporation
into DNA over 16 h as described in Section 2. One-way AN-
OVA followed by Sche¡e test, n = 4^6. Values are mean þ
S.E.M.
Fig. 4. E¡ect of immunodepletion of individual growth factors
and matrix proteins on CF-CM-induced DNA synthesis in hu-
man endothelial cells. VEGF, PDGF-A, PDGF-B, bFGF,
TGF-L1, ¢bronectin and thrombospondin-1 were removed from
CF-CM by immunoprecipitation with speci¢c antibodies and
the resulting CF-CM was used for its e¡ect on DNA synthesis
as described in Section 2. The bargraphs show the percentage
by which the mean e¡ect of whole CF-CM decreased after indi-
vidual removal of each factor.
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activity was rapid (10 min) and transient because
after 1 h treatment with CF-CM the level of MBP
phosphorylation was comparable to that in untreated
cells (Fig. 6). These results demonstrate the activa-
tion of MAP kinase ERK2 by CF-CM and are con-
sistent with those in Fig. 1, demonstrating that CF-
CM-induced DNA synthesis in HUVEC is depen-
dent on activation of MAP kinases.
3.4. Protective e¡ect of CF-CM under hypoxia
The possibility that the stimulatory e¡ect of CF-
CM may protect endothelial cells under stressful
stimuli was tested by measuring DNA synthesis in
HUVEC under hypoxia, in the presence and absence
of CF-CM. The results showed that in the absence of
CF-CM hypoxia caused a signi¢cant decrease (70%,
P6 0.001) in DNA synthesis (Fig. 7). The presence
of CF-CM, however, resulted in a signi¢cant reversal
of this inhibitory e¡ect so that the net e¡ect was only
20% inhibition. This protective e¡ect was compara-
ble in magnitude to the e¡ect of 10% FBS (Fig. 5).
To gain insights into the e¡ect of CF-CM on endo-
thelial cell survival under hypoxia, we determined the
expression of Bcl2, a survival-associated protein, and
p53, apoptosis-associated transcription factor, in
HUVEC. The results showed a higher level of Bcl2
expression in HUVEC under hypoxia in the presence
of CF-CM compared to HUVEC under hypoxia but
in the absence of CF-CM (Fig. 7). A moderate in-
crease in Bcl2 expression in HUVEC in the presence
of CF-CM was also observed under normoxia (Fig.
7). The expression of p53 in HUVEC did not change
by CF-CM (data not shown).
4. Discussion
The results of this study provide substantial evi-
dence in support of a role for cardiac ¢broblasts in
the regulation of endothelial cell proliferation. Spe-
ci¢cally, the results demonstrate that: (1) human car-
diac ¢broblasts release soluble factors including an
array of growth factors and matrix proteins with
known e¡ects on endothelial cell growth and di¡er-
entiation including VEGF, bFGF, PDGF, TGF-L1,
thrombospondin-1 and ¢bronectin. Of these, TGF-L1
[4] and PDGF [7] have been previously described;
(2) although soluble factors contain both stimulators
and inhibitors of endothelial cell proliferation, their
net e¡ect is stimulation of DNA synthesis in human
endothelial cells; (3) cardiac ¢broblasts appear to
provide protection to endothelial cells under hypoxia
as evidenced by a signi¢cant reversal of hypoxia-in-
duced inhibition of DNA synthesis and by enhanced
expression of survival-associated protein, bcl2, in en-
Fig. 7. E¡ect of CF-CM on DNA synthesis and the expression
of Bcl2 in human endothelial cells under hypoxia. In panel A,
quiescent HUVEC were treated with [3H]thymidine (6 WCi/ml)
under normoxic condition (21% oxygen) or hypoxia (2% oxy-
gen) for 16 h in the presence and absence of CF-CM or 10%
FBS. DNA synthesis was determined by measurement of
[3H]thymidine incorporation as described in Section 2. One-way
ANOVA followed by Sche¡e test, n = 4^6. Values are mean þ
S.E.M. In panel B, the expression of Bcl2 in the lysate of HU-
VEC grown under the same conditions as those in panel A was
determined by Western analysis as described in Section 2. The
bargraphs show the results of densitometry scanning of Bcl2
signals on autoradiograph normalized to the results of densi-
tometry scanning of signals obtained by incubating the same
blot with anti-vimentin antibody. The autoradiograph is repre-
sentative of two independent experiments.
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dothelial cells in the presence of CF-CM under hyp-
oxia.
The observed stimulation of DNA synthesis in en-
dothelial cells by whole CF-CM is consistent with the
presence of growth factors. The results with heparin-
depleted CF-CM con¢rm the presence of heparin-
binding inhibitors and indicate that the stimulatory
e¡ect of whole CF-CM is the net e¡ect of factors
with both inhibitory and stimulatory e¡ects on
DNA synthesis. The results of Western analysis sup-
port this notion and demonstrated that in addition to
growth factors, thrombospondin-1, a heparin-bind-
ing matrix protein and an established inhibitor of
endothelial cell proliferation, is also present in whole
CF-CM. The heparin-depleted CF-CM consists
mostly of non-heparin-binding factors and perhaps
only trace amounts of all heparin-binding factors,
whereas whole CF-CM contains both heparin-bind-
ing and non-heparin-binding proteins. Accordingly,
the enhanced e¡ect of heparin-depleted CF-CM on
DNA synthesis suggests that in addition to known
heparin-binding growth factors, whole CF-CM con-
tains other growth factor(s) all or a number of which
are not heparin-binding proteins and the e¡ect of
which in the absence of heparin-binding inhibitors
of DNA synthesis is enhanced. Future studies must
determine the nature of all factors produced by hu-
man cardiac ¢broblasts and the complex stoichiom-
etry between the inhibitory and stimulatory factors
which results in a net stimulatory e¡ect on DNA
synthesis in endothelial cells.
The ¢ndings demonstrating drastic inhibition of
CF-CM-induced DNA synthesis after immunodeple-
tion of soluble ¢bronectin point to the role that this
matrix protein may play in the stimulation of DNA
synthesis either via direct interaction with endothelial
cells or indirectly by binding to growth factors
present in CF-CM. The results with RGD peptide,
however, suggest that even if the e¡ect of ¢bronectin
is mediated directly through its interactions with en-
dothelial cells, these interactions are not via RGD-
sensitive (K5L1, KvL3 and K3L1) integrins [21]. An
alternative mechanism by which the removal of solu-
ble ¢bronectin causes a signi¢cant reduction in CF-
CM-induced DNA synthesis, is a potential associa-
tion of ¢bronectin with one or any number of growth
factors present in CF-CM, hence their co-precipita-
tion with anti-¢bronectin antibody.
Thrombospondin-1 is a potent anti-angiogenic
molecule with known inhibitory e¡ects on prolifera-
tion of endothelial cells [19]. This matrix protein
binds the cell surface molecules including integrins
KvL3 and K2L3 and integrin-associated molecules
via the RGD sequence located at its carboxyl termi-
nal. Immunodepletion of thrombospondin-1 from
CF-CM, however, did not result in enhancement of
CF-CM-induced DNA synthesis, rather caused a
modest inhibition of the CF-CM-induced e¡ect.
These results indicate that thrombospondin-1 is not
the only heparin-binding inhibitor present in CF-
CM. On the other hand, since the results with
RGD peptide ruled out the possibility of a role for
RGD binding in CF-CM-induced DNA synthesis,
the e¡ects of thrombospondin-1 are likely not medi-
ated via RGD-dependent mechanisms. Thrombo-
spondin-1 binds to a variety of growth factors in-
cluding PDGF [22]. Thus it is likely that the
immunodepletion of thrombospondin-1 causes co-
precipitation of a number of growth factors which,
in turn, leads to inhibition of CF-CM-induced DNA
synthesis. Thrombospondin-1 is also known to be
necessary for activation of latent TGF-L1 [23].
Although in this study the contribution of TGF-L1
to CF-CM-induced stimulation of DNA synthesis is
relatively modest, the immunodepletion of thrombo-
spondin-1 may indeed prevent TGF-L1 activation,
hence inhibition of CF-CM-induced DNA synthesis.
These possibilities must be determined in further de-
tail.
The ¢ndings of the present study demonstrating a
partial, but signi¢cant reversal of hypoxia-induced
inhibition of DNA synthesis in HUVEC by CF-
CM are consistent with the presence of an ensemble
of growth factors including VEGF and bFGF in CF-
CM. The enhanced expression of Bcl2 in HUVEC
under hypoxia, however, suggests that in addition
to the compensatory e¡ect of growth factors, protec-
tive mechanisms including those related to cell sur-
vival are also activated by CF-CM. Although in the
present study we did not detect any CF-CM-induced
changes in the level of p53 in HUVEC (data not
shown), future studies must determine the regulation
of other apoptosis-associated proteins and transcrip-
tion factors in endothelial cells by cardiac ¢broblasts.
In summary, the results of the present study sug-
gest that cardiac ¢broblasts by releasing an array of
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growth factors and soluble forms of matrix proteins
may play a regulatory role in the proliferation of
endothelial cells. Furthermore, soluble factors re-
leased by cardiac ¢broblasts may play a role in pro-
tecting human endothelial cells under hypoxia. Fu-
ture studies aimed at understanding the interplay and
stoichiometry of diverse factors released by cardiac
¢broblasts may o¡er new possibilities for ¢ne tuning
the function of cardiac ¢broblasts and possibly al-
lowing their use as biological vehicles for delivery
of an ensemble of factors necessary for the stimula-
tion or suppression of the proliferative response in
endothelial cells in the heart.
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